Application of nasal sprays for treatment of allergic rhinitis and changes in local gene expressio

Phase 4

Completed

• Conditions: allergic rhinitis; Inflammatory and Immune System - Allergies

• Registration Number: ACTRN12616001439437
• Lead Sponsor: Griffith University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-10-14
• Study Completion: 2018-05-28
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

For inclusion into the study participants will: have a more than 2 year history of allergic rhinitis, have moderate/severe persistent allergic rhinitis based on ARIA classification, score 5 cm or greater on a visual analogue scale of symptom severity, score 6 or greater on a total nasal symptom score survey, have a positive skin prick test and/or radio-allergosorbent test to Dermatophahoides pteronyssinus or D. farnae.

Exclusion Criteria

Participants will be excluded from participating if they: have non-allergic rhinitis, test negative on skin prick test to Dermatophagoides pteronyssinus or D. farnae, have consumed probiotics or prebiotics in the previous 12 weeks, have undergone treatment with systemic corticosteriods in the previous 6 months, use immune-modulating medications, have history of respiratory diseases such as asthma, COPD or other medical conditions such as glaucoma or hepatic impairment, reports excessive alcohol consumption, have history of nasal polyposis, nasal ulcers, recent nasal surgery or nasal trauma, are pregnant, have current illness with bacterial or viral infection, have known hypersensitivity to Azep, Flixonase or Dymista .

Study & Design

• Study Type: Interventional
• Study Design: Not specified